A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
DOI10.1080/07474946.2016.1238250zbMath1358.62097OpenAlexW2554661229WikidataQ115006072 ScholiaQ115006072MaRDI QIDQ2958397
Steven B. Kim, Daniel L. Gillen
Publication date: 1 February 2017
Published in: Sequential Analysis (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/07474946.2016.1238250
adaptive designphase I clinical trialsindividual- and population-level ethicsmultiple Bayesian adaptive designs
Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Bayesian inference (62F15) Bayesian problems; characterization of Bayes procedures (62C10) Sequential statistical design (62L05)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Continual reassessment and related dose-finding designs
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Penalized optimal designs for dose-finding
- Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
- Bayesian Optimal Designs for Phase I Clinical Trials
- Design and Analysis of Phase I Clinical Trials
- Bayesian decision procedures based on logistic regression models for dose-finding studies
This page was built for publication: A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
